Editorial board

Editor in Chief:

M. Ian Phillips, Director of the Center for Rare Disease Therapies, Keck Graduate Institute, USA

Editorial Board:

Sabina Antoniu, Pulmonary Disease Division, University of Medicine and Pharmacy, Romania

Martin Braddock, Global Medicines Development, AstraZeneca R&D, UK

Maria Luisa Brandi, Unit of Bone and Mineral Metabolism, University of Florence, Italy

Roberto Giugliani, Department of Genetics, Federal University of Rio Grande do Sul, Brazil

Stephen Groft, Director, Office of Rare Diseases, National Institutes of Health, USA

Aaron S. Kesselheim, Harvard Medical School and Brigham and Women's Hospital, USA

Stephen Kingsmore, Center for Pediatric Genomic Medicine, Children's Mercy Hospitals and Clinics, USA

Alex MacKenzie, Pediatrics, CHEO, University of Ottawa, Canada

Maria Mavris, EURORDIS - European Organisation for Rare Diseases, France

Khue Nguyen, University of California, San Diego, USA

Daniel O'Connor, Medicines and Healthcare Products Regulatory Agency, UK

Manuel Posada, Director, Research Institute for Rare Diseases, Instituto de Salud Carlos III, Spain

Peter L. Saltonstall, President and CEO, National Organization for Rare Disorders (NORD), USA

Michael Shy, Division of Neuromuscular Medicine, University of Iowa, USA

Ali Taher, Division of Hematology/Oncology, American University of Beirut Medical Centre, Lebanon

Eleftherios Tsiridis, Academic Department of Trauma and Orthopaedics, University of Leeds, UK